** Shares of MBX Biosciences MBX.O climb 6% to $43.42

** The biotech firm says preliminary blinded data for obesity drug MBX 4291 showed about 7% mean weight loss at eight weeks by targeting appetite and metabolism-related hormones

** Adds that drug designed for once-monthly dosing with gradual release profile supporting steady exposure

** Only one mild gastrointestinal side effect reported; no serious adverse events - MBX

** Says 12-week data due Q4 2026, key for confirming durability

** Names new next-gen obesity candidate MBX 5765, targeting multiple pathways for improved efficacy

** The minimal gastrointestinal side effects seen so far are an encouraging sign that the prodrug platform could support a differentiated tolerability profile - TD Cowen analysts

** MBX says it achieved proof of concept for imapextide in low blood sugar condition after weight-loss surgery

** Including session's move, stock up ~38% YTD